67159-88-0

Basic information

• Product Name: 6-bromo-1,1-dimethylindan
• Synonyms: 6-bromo-1,1-dimethylindan;6-bromo-1,1-dimethyl-2,3-dihydro-1H-indene
• CAS NO: 67159-88-0
• Molecular Formula: C11H13Br
• Molecular Weight: 225.12492
• EINECS: -0
• Mol File: 67159-88-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-bromo-1,1-dimethylindan(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-1,1-dimethylindan(67159-88-0)
• EPA Substance Registry System: 6-bromo-1,1-dimethylindan(67159-88-0)

Safety Data

• Hazardous Substances Data: 67159-88-0(Hazardous Substances Data)

Upstream product

• 589-15-1 1-bromomethyl-4-bromobenzene 
• 14548-39-1 6-bromoindan-1-one 
• 544-97-8 dimethyl zinc(II) 
• 84648-11-3 1-(4-bromophenyl)-3-methyl-2-butanol 

Downstream Products

• 84680-80-8 1-(1,1-dimethyl-6-indanyl)-4-phenyl-2-butyne-1,4-dione 
• 84680-79-5 1-(1,1-dimethyl-6-indanyl)-4-phenyl-2-butyne-1,4-diol 
• 84680-81-9 3-benzoyl-2,5-diphenyl-4-(1,1-dimethyl-6-indanoyl)thiophene 
• 84648-10-2 1-(1,1-dimethyl-6-indanyl)-3,4,6-triphenylthieno<3,4-c>thiophene 
• 67159-85-7 5-bromo-3,3-dimethyl-2,3-dihydro-1H-inden-1-one 
• 1396777-58-4 6-bromo-4,4-dimethyl-3,4-dihydroisoquinolin-1(2H)-one 

Relevant articles and documents

NOVEL DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present invention provides a novel compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof. The compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.

KCNQ 2-5 CHANNEL ACTIVATOR

An object of the present invention is to provide a novel compound having a strong opening action with respect to KCNQ2-5 channels. A compound represented by the general formula (I) (wherein the definition of each group is as described in the specification) is provided. The compound represented by the general formula (I) has a strong opening action with respect to KCNQ2-5 channels, and therefore is useful as a prophylactic and/or therapeutic agent for a KCNQ2-5 channel-related disease (for example, dysuria, overactive bladder, or the like).

aromatic compound having fused cyclic substituent in aromatic ring and organic light-emitting diode including the same

The present invention relates to a compound having a cyclic substituent fused with a cyclic ring and an organic light emitting diode including the same, and more particularly, to a compound for an organic light emitting diode represented by chemical formula A and an organic light emitting diode including the same. In chemical formula A, X is a substituent having structural formula X, Y is a substituent of structural formula Y1, n is an integer from 1 to 4, and structural formulas X and Y1 are the same as described in detailed description of the present invention.

What can13C and1H NMR lithiation shifts tell us about the charge distribution in α-arylvinyllithium compounds?

The energetically stabilizing delocalization of negative electric charge from the Li[sbnd]C(α) bond into the aryl π system of α-arylvinyllithiums, Ar[sbnd]C(Li)[dbnd]CH2, is most efficient with an orthogonal relationship of the aryl ring plane

aromatic compound having fused cyclic substituent in aromatic ring and organic light-emitting diode including the same

The present invention refers to to the aromatic ring-fused ring withdrawing substituent and a compound having an same relates to organic light emitting device including, more specifically a represented by [formula A] an alkali-soluble polymer resin compound for an organic light-emitting device including organic light emitting device is characterized in that the. [Formula A] In said [formula A], X has a dementia drug; and shows strong X having substituted group, Y has a dementia drug; and shows strong formula selected from the group consisting Y1 to Y5 having one of substituted group, the n being integers, of 4 to 1, the Y5 formula to Y1 formula and X formula detailed description of the invention is described. (by machine translation)

MST1 KINASE INHIBITORS AND METHODS OF THEIR USE

Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders.

INHIBITORS OF SPHINGOSINE KINASE

The present invention relates to compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, M1, M2, M3, M4, Y1, Y2, V, W, n, m and o have the meanings given in Claim 1, and physiologically acceptable salts, derivatives, prodrugs, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for use in the treatment of diseases which are influenced by inhibition of Sph kinase 1.

Multicyclic bis-amide MMP inhibitors

The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.

DISUBSTITUTED CHALCONE OXIMES HAVING RARγ RETINOID RECEPTOR ANTAGONIST ACTIVITY

Compounds of the formula where the variables have the values described in the specification are antagonists of RARγ retinoid receptors.

Theoretical Study of Thienothiophene, a Nonclassical Thiophene System

The reaction of thienothiophene with dicyanoacetylene is examined as a model for cycloadditions of derivatives of this ring system with dipolarophiles utilizing the MINDO/3 approximation in MO theory.Extrusion of elemental sulfur as an atomic speci